Stempeutics

Stempeutics out licenses its novel stem cell product “Stempeucel-DFU” to Cipla for treating non healing Diabetic Foot Ulcer (DFU)

Diabetic foot is one of the most significant and devastating complications of diabetes Out of approx. 70 million diabetics in India,…

5 years ago

Alkem Laboratories inks out-licensing Treat Stempeutics Research

Mumbai, February 10, 2018:  Pharma Major Alkem Laboratories has inked an out-licensing deal with Stempeutics Research, a group company of…

6 years ago

Stempeutics signed a co-development agreement with Alkem for its stem cell therapy product Stempeucel® for treating Osteoarthritis of the knee

Osteoarthritis (OA) Knee is one of the most common & debilitating disease of joint with around 30 Mn people in…

6 years ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420